Aprea Therapeutics

APRE

Market cap $8.79M

APRE Hedge Fund Activity: Q1 2026 in Review

22 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2026, worth a combined $1.71M — up 18% from $1.45M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new APRE positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.

The largest buyer was AIGH Capital Management, adding an estimated $507K. The largest seller was Murchinson, exiting entirely with an estimated $290K sold.

• 22 institutional investors held Aprea Therapeutics (APRE) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $1.71M of Aprea Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
• 7 funds opened new Aprea Therapeutics positions in Q1 2026 and 6 closed out, a net change of +1 holder.
• The largest Aprea Therapeutics buyer in Q1 2026 was AIGH Capital Management, an estimated $507K added.
• The largest Aprea Therapeutics seller in Q1 2026 was Murchinson, an estimated $290K sold.

Based on aggregated 13F filings for Q1 2026.